While attempting to stave off a legal challenge to its patent on the blood thinner Plavix, Bristol-Myers Squibb manages to sign off on fine print that gives Canadian generic drugmaker Apotex five days to flood the market with an off-brand version.
By the time Bristol can get an injunction to turn off that spigot, Apotex has filled pharmacy warehouses with its lower-priced meds, costing Bristol more than $525 million in profit and CEO Peter Dolan his job.
What are you, on drugs?
|  See the video, test your 'Dumbest' knowledge, and check out our 'Sex, drugs, and celebrities' gallery. (more)  Business 2.0's Adam Horowitz and comedian Mo Rocca ponder the stupidity of this tactless treatment of fired workers. (more)  |
